The Functional Assessment of Cancer Therapy-General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma

Kathleen J. Yost, Carrie A. Thompson, David T. Eton, Cristine Allmer, Shawna L. Ehlers, Thomas M. Habermann, Tait D. Shanafelt, Matthew J. Maurer, Susan L. Slager, Brian K. Link, James R. Cerhan

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Quality of life (QoL) is an important outcome in patients with non-Hodgkin lymphoma (NHL). We assessed the validity of administering the Functional Assessment of Cancer Therapy-General (FACT-G) at 12-month intervals over 3 years in a longitudinal study of 611 prospectively enrolled, newly diagnosed patients with NHL. We evaluated corrected item-total correlation and percent missing to identify items that may be less useful in certain NHL patient subgroups. The FACT-G subscales and total score demonstrated good internal consistency reliability, convergent validity and known-groups validity. Most scores also demonstrated good responsiveness to change. Questions that could be problematic included GE3 (losing hope) and GP2 (nausea) for patients in remission, and GP5 (bothered by side effects) for patients being observed. Overall, the FACT-G was a valid measure for monitoring QoL over time in patients with NHL. However, sensitivity analyses based on subscale scoring that excludes potentially problematic items may be warranted.

Original languageEnglish (US)
Pages (from-to)290-297
Number of pages8
JournalLeukemia and Lymphoma
Volume54
Issue number2
DOIs
StatePublished - Feb 2013

Keywords

  • Non-Hodgkin lymphoma
  • Patient-reported outcomes
  • Quality of life
  • Validation studies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The Functional Assessment of Cancer Therapy-General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this